H.C. Wainwright Thinks BiomX’s Stock is Going to Recover

In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on BiomX (PHGEResearch Report), with a price target of $20.00. The company’s shares closed last Wednesday at $2.74, close to its 52-week low of $2.66.

According to TipRanks.com, Pantginis is a 4-star analyst with an average return of 15.2% and a 41.0% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Actinium Pharmaceuticals.

BiomX has an analyst consensus of Moderate Buy, with a price target consensus of $22.50.

See the top stocks recommended by analysts >>

BiomX’s market cap is currently $76.97M and has a P/E ratio of -1.90. The company has a Price to Book ratio of 1.66.

Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PHGE in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BiomX Ltd engages in developing bacteriophage-based therapies for the treatment and prevention of diseases stemming from dysbiosis of the microbiome. The company was founded in March 2015 and is headquartered in Ness Ziona, Israel.